{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:18:06Z","timestamp":1787793486049,"version":"build-2784847793"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.autrev.2025.103953","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:24:23Z","timestamp":1761186263000},"page":"103953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["IL-33 in Spondyloarthritis, the missing key"],"prefix":"10.1016","volume":"25","author":[{"given":"Frank","family":"Verhoeven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalil","family":"Hannani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Demougeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10089","key":"10.1016\/j.autrev.2025.103953_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2025.103953_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103953_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0016-5085(89)91557-6","article-title":"Ileocolonoscopy in seronegative spondylarthropathy","volume":"96","author":"De Vos","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103953_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/art.42289","article-title":"Both disease activity and HLA-B27 status are associated with gut microbiome dysbiosis in spondyloarthritis patients","volume":"75","author":"Berland","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103953_bb0025","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.semarthrit.2021.04.015","article-title":"Intestinal permeability in spondyloarthritis and rheumatoid arthritis: a systematic review of the literature","volume":"51","author":"Hecquet","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103953_bb0030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","article-title":"Increased intestinal permeability is associated with later development of Crohn\u2019s disease","volume":"159","author":"Turpin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103953_bb0035","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1053\/j.gastro.2022.07.004","article-title":"Altered gut microbiome composition and function are associated with gut barrier dysfunction in healthy relatives of patients with Crohn\u2019s disease","volume":"163","author":"Leibovitzh","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103331","article-title":"Cytokines and intestinal epithelial permeability: a systematic review","volume":"22","author":"Meyer","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-023-03069-9","article-title":"Increased gut permeability and intestinal inflammation precede arthritis onset in the adjuvant-induced model of arthritis","volume":"25","author":"Hecquet","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103953_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.623874","article-title":"IL-23 inhibition in ankylosing spondylitis: Where did it go wrong?","volume":"11","author":"Baeten","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103953_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.553742","article-title":"Innate cells: the alternative source of IL-17 in axial and peripheral Spondyloarthritis?","volume":"11","author":"Rosine","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0060","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12079-018-0464-4","article-title":"A network map of IL-33 signaling pathway","volume":"12","author":"Pinto","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.autrev.2025.103953_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121868","article-title":"IL-33\u2019s role in the gut immune system: a comprehensive review of its crosstalk and regulation","volume":"327","author":"Kaur","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2025.103953_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","article-title":"Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation","volume":"55","author":"Bessa","year":"2014","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.smim.2013.10.006","article-title":"Special aspects of interleukin-33 and the IL-33 receptor complex","volume":"25","author":"Martin","year":"2013","journal-title":"Semin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.187.5.787","article-title":"Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells","volume":"187","author":"Xu","year":"1998","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.autrev.2025.103953_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/f61a5d49-25e7-47ce-8509-6478df526886","article-title":"Hypoxia-inducible factor-1\u03b1 and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis","volume":"8","author":"Hu","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2025.103953_bb0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood.2021011010","article-title":"Neutrophil HIF-1\u03b1 stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle","volume":"139","author":"Willson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103953_bb0105","article-title":"Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1\u03b1","author":"Hai","year":"2024","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.autrev.2025.103953_bb0110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143729","article-title":"Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells","volume":"131","author":"Liikanen","year":"2021","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0115","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/eji.201141629","article-title":"IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells","volume":"41","author":"Yang","year":"2011","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4049\/jimmunol.1401344","article-title":"Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells","volume":"194","author":"Gao","year":"2015","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2025.103953_bb0125","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1073\/pnas.1418549112","article-title":"T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses","volume":"112","author":"Baumann","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103953_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cytogfr.2024.11.005","article-title":"IL-33 in cancer immunotherapy: Pleiotropic functions and biological strategies","volume":"85","author":"Che","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2025.103953_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217584","article-title":"PRTN3 promotes IL33\/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma","volume":"616","author":"Jiang","year":"2025","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.autrev.2025.103953_bb0140","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.4049\/jimmunol.1400481","article-title":"IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R\/ST2+ regulatory T cells","volume":"193","author":"Matta","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.immuni.2015.06.021","article-title":"An Interleukin-33-Mast Cell-Interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers","volume":"43","author":"Morita","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2025.103953_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156015","article-title":"IL-33\/ST2 axis in autoimmune disease","volume":"158","author":"Shakerian","year":"2022","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41385-020-0273-y","article-title":"IL-17 production by tissue-resident MAIT cells is locally induced in children with pneumonia","volume":"13","author":"Lu","year":"2020","journal-title":"Mucosal Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103953_bb0160","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41423-024-01183-5","article-title":"HIF-1\u03b1 and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model","volume":"21","author":"Nakamura","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103953_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2025.137257","article-title":"Interleukin-33 modulates NET formation via an autophagy-dependent manner to promote neutrophilic inflammation in cigarette smoke-exposure asthma","volume":"487","author":"Liu","year":"2025","journal-title":"J Hazard Mater"},{"issue":"9","key":"10.1016\/j.autrev.2025.103953_bb0170","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103953_bb0175","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1136\/ard.2009.120113","article-title":"Role of interleukin 33 in human immunopathology","volume":"69","author":"Murphy","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103953_bb0180","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s10067-011-1843-x","article-title":"Serum levels of IL-33 is increased in patients with ankylosing spondylitis","volume":"30","author":"Han","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2310\/JIM.0b013e31828deed2","article-title":"Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor","volume":"61","author":"Li","year":"2013","journal-title":"J Invest Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5114\/reum.2015.50551","article-title":"Cytokine profiles in axial spondyloarthritis","volume":"53","author":"Madej","year":"2015","journal-title":"Reumatologia"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/03009742.2012.735700","article-title":"Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis","volume":"42","author":"Li","year":"2013","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/rheumatology\/ket323","article-title":"Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis","volume":"53","author":"Ciccia","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0205","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1038\/s41598-018-25722-z","article-title":"Increase In Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis","volume":"8","author":"Rosine","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/03009742.2014.882408","article-title":"Single nucleotide polymorphisms of the interleukin-33 (IL-33) gene are associated with ankylosing spondylitis in Chinese individuals: a case-control pilot study","volume":"43","author":"Fan","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0215","first-page":"437","article-title":"Bone changes and curative effect of infliximab in patients with ankylosing spondylitis","volume":"20","author":"Li","year":"2020","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0220","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10067-022-06070-w","article-title":"The impact of anti-TNF treatment on Wnt signaling, noggin, and cytokine levels in axial spondyloarthritis","volume":"41","author":"Atas","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103953_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0230","doi-asserted-by":"crossref","first-page":"21094","DOI":"10.1038\/s41598-020-78204-6","article-title":"Anti-IL-17\u00a0A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis","volume":"10","author":"Kaaij","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0235","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/ard-2022-223791","article-title":"Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis","volume":"82","author":"Tavasolian","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103953_bb0240","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00535-010-0245-1","article-title":"Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis","volume":"45","author":"Kobori","year":"2010","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0245","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2009.11.001","article-title":"IL-33 is upregulated in colonocytes of ulcerative colitis","volume":"128","author":"Seidelin","year":"2010","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2025.103953_bb0250","doi-asserted-by":"crossref","first-page":"35403","DOI":"10.1038\/srep35403","article-title":"Loss of interleukin 33 expression in colonic crypts - A potential marker for disease remission in ulcerative colitis","volume":"6","author":"Gundersen","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0255","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.2353\/ajpath.2010.100378","article-title":"Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts","volume":"177","author":"Sponheim","year":"2010","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae158","article-title":"Mucosal cytokine expression associated with deep endoscopic mucosal healing in ulcerative colitis","volume":"19","author":"Uchiyama","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103953_bb0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/00365521.2019.1710245","article-title":"Mucosal gene transcription of ulcerative colitis in endoscopic remission","volume":"55","author":"Arkteg","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0270","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jim-2016-000062","article-title":"Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity","volume":"64","author":"Boga","year":"2016","journal-title":"J Invest Med"},{"issue":"104","key":"10.1016\/j.autrev.2025.103953_bb0275","first-page":"1442","article-title":"Interleukins IL-33 and IL-17\/IL-17A in patients with ulcerative colitis","volume":"57","author":"Ajdukovi\u0107","year":"2010","journal-title":"Hepatogastroenterology"},{"issue":"17","key":"10.1016\/j.autrev.2025.103953_bb0280","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1073\/pnas.0912678107","article-title":"Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1\/Th2 driven enteritis","volume":"107","author":"Pastorelli","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2025.103953_bb0285","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/gutjnl-2011-301785","article-title":"Neutralization of the interleukin-33\/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice","volume":"62","author":"Sedhom","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2025.103953_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/913041","article-title":"IL-33 aggravates DSS-induced acute colitis in mouse colon lamina propria by enhancing Th2 cell responses","volume":"2015","author":"Zhu","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.autrev.2025.103953_bb0295","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00535-014-0982-7","article-title":"IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis","volume":"50","author":"Seidelin","year":"2015","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0300","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/cei.12896","article-title":"Hypoxia inducible factor-1\u03b1-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease","volume":"187","author":"Sun","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103953_bb0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2017.02.006","article-title":"IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis","volume":"46","author":"Zhu","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0310","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41598-017-00840-2","article-title":"Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease","volume":"7","author":"Seo","year":"2017","journal-title":"Sci Rep"},{"issue":"40","key":"10.1016\/j.autrev.2025.103953_bb0315","doi-asserted-by":"crossref","first-page":"E9362","DOI":"10.1073\/pnas.1803613115","article-title":"IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair","volume":"115","author":"Lopetuso","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.autrev.2025.103953_bb0320","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","article-title":"Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease","volume":"175","author":"Kinchen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103953_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669787","article-title":"IL-33 drives expansion of Type 2 innate lymphoid cells and regulatory T cells and protects mice from severe, acute colitis","volume":"12","author":"Ngo Thi Phuong","year":"2021","journal-title":"Front Immunol"},{"issue":"7950","key":"10.1016\/j.autrev.2025.103953_bb0330","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-022-05628-7","article-title":"Active eosinophils regulate host defence and immune responses in colitis","volume":"615","author":"Gurtner","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.autrev.2025.103953_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062144","article-title":"Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease","volume":"8","author":"Latiano","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2025.103953_bb0340","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.40183","article-title":"Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of Spondyloarthritis","volume":"69","author":"Asquith","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103953_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.589639","article-title":"Genetic association of Interleukin 33\/ST2 polymorphisms with Behcet\u2019s Uveitis","volume":"12","author":"Pei","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.humimm.2015.03.011","article-title":"Interleukin-33 and Beh\u00e7et disease: another cytokine among others","volume":"76","author":"Hamzaoui","year":"2015","journal-title":"Hum Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0355","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1002\/eji.201444671","article-title":"IL-33 attenuates the development of experimental autoimmune uveitis","volume":"44","author":"Barbour","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2025.103953_bb0360","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exer.2015.06.018","article-title":"Expression profile of IL-1 family cytokines in aqueous humor and sera of patients with HLA-B27 associated anterior uveitis and idiopathic anterior uveitis","volume":"138","author":"Zhao","year":"2015","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0365","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1566524015666150731100012","article-title":"Cytokine expression profile in Aqueous Humor and Sera of patients with Acute Anterior Uveitis","volume":"15","author":"Chen","year":"2015","journal-title":"Curr Mol Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103953_bb0370","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/1566524018666180207154938","article-title":"Association of IL33 and IL1RAP Polymorphisms With Acute Anterior Uveitis","volume":"17","author":"Huang","year":"2018","journal-title":"Curr Mol Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103953_bb0375","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/eji.201041360","article-title":"IL-33 induces skin inflammation with mast cell and neutrophil activation","volume":"41","author":"Hueber","year":"2011","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103953_bb0380","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1073\/pnas.1000803107","article-title":"IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin","volume":"107","author":"Theoharides","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.2012.04618.x","article-title":"Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor","volume":"169","author":"Suttle","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103953_bb0390","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2340\/00015555-2018","article-title":"Experimentally induced psoriatic lesions associate with rapid but transient decrease in interleukin-33 immunostaining in epidermis","volume":"95","author":"Suttle","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0395","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/exd.12027","article-title":"IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation","volume":"21","author":"Balato","year":"2012","journal-title":"Exp Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103953_bb0400","doi-asserted-by":"crossref","first-page":"689","DOI":"10.34172\/aim.2021.99","article-title":"Serum expression of IL-33 and ST2 in patients with Psoriasis Vulgaris","volume":"24","author":"Dong","year":"2021","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.autrev.2025.103953_bb0405","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8465083","article-title":"Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris","volume":"2020","author":"Borsky","year":"2020","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.autrev.2025.103953_bb0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdermsci.2013.04.014","article-title":"Expression of IL-33 in the epidermis: The mechanism of induction by IL-17","volume":"71","author":"Meephansan","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00403-014-1447-9","article-title":"IL-33 is regulated by TNF-\u03b1 in normal and psoriatic skin","volume":"306","author":"Balato","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.autrev.2025.103953_bb0420","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/imm.13203","article-title":"Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response","volume":"160","author":"Chen","year":"2020","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12964-023-01075-7","article-title":"IL-33-mediated activation of mast cells is involved in the progression of imiquimod-induced psoriasis-like dermatitis","volume":"21","author":"Zhou","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"683","key":"10.1016\/j.autrev.2025.103953_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj3289","article-title":"IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases","volume":"15","author":"Lavazais","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103953_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110480","article-title":"Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod","volume":"121","author":"Fu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103953_bb0440","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212397","article-title":"A dysregulated sebum-microbial metabolite-IL-33 axis initiates skin inflammation in atopic dermatitis","volume":"219","author":"Qiu","year":"2022","journal-title":"J Exp Med"},{"issue":"14","key":"10.1016\/j.autrev.2025.103953_bb0445","article-title":"Butyrate inhibits Staphylococcus aureus-aggravated dermal IL-33 expression and skin inflammation through histone deacetylase inhibition","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103953_bb0450","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.24305","article-title":"Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis","volume":"60","author":"Palmer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2025.103953_bb0455","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.4049\/jimmunol.1003487","article-title":"IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss","volume":"186","author":"Zaiss","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41467-019-13853-4","article-title":"GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis","volume":"11","author":"Regan-Komito","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.autrev.2025.103953_bb0465","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1187","article-title":"Blockade of IL-33 signaling attenuates osteoarthritis","volume":"9","author":"He","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0470","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/imm.12020","article-title":"Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice","volume":"138","author":"Qiu","year":"2013","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.autrev.2025.103953_bb0475","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jbmr.269","article-title":"Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells","volume":"26","author":"Schulze","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.autrev.2025.103953_bb0480","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cyto.2015.10.005","article-title":"Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"77","author":"Lee","year":"2016","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0485","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/eji.201646774","article-title":"Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage","volume":"47","author":"Raimondo","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2025.103953_bb0490","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fimmu.2017.01312","article-title":"Osteoblast hypoxia-inducible factor-1\u03b1 pathway activation restrains osteoclastogenesis via the Interleukin-33-MicroRNA-34a-Notch1 pathway","volume":"8","author":"Kang","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0495","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12533","article-title":"IL-33 guides osteogenesis and increases proliferation and pluripotency marker expression in dental stem cells","volume":"52","author":"Kukolj","year":"2019","journal-title":"Cell Prolif"},{"issue":"1","key":"10.1016\/j.autrev.2025.103953_bb0500","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/s41467-024-46746-2","article-title":"The IL-33\/ST2 axis is protective against acute inflammation during the course of periodontitis","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.autrev.2025.103953_bb0505","doi-asserted-by":"crossref","first-page":"E686","DOI":"10.1152\/ajpendo.00157.2024","article-title":"Circulating interleukin-33 levels in obesity and type 2 diabetes: a systematic review and meta-analysis","volume":"327","author":"Missous","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.autrev.2025.103953_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112455","article-title":"Dynamic regulation of IL-33 in the obesity pathogenesis: spatiotemporal specificity and functional paradoxes","volume":"229","author":"Cui","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.autrev.2025.103953_bb0515","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","article-title":"IL-33 (Interleukin 33)\/sST2 axis in hypertension and heart failure","volume":"72","author":"Ghali","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.autrev.2025.103953_bb0520","first-page":"2167","article-title":"Roles of IL-33 in the pathogenesis of cardiac disorders","volume":"248","author":"Jiang","year":"2023","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.autrev.2025.103953_bb0525","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2023.06.003","article-title":"Modulation of IL-33\/ST2 signaling as a potential new therapeutic target for cardiovascular diseases","volume":"71\u201372","author":"Thanikachalam","year":"2023","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:05:23Z","timestamp":1767099923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1568997225002149"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103953","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-33 in Spondyloarthritis, the missing key","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103953"}}